Welcome!

News Feed Item

Nuvo Research® announces 2014 second quarter results

MISSISSAUGA, ON, July 30, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced its financial and operational results for the second quarter ended June 30, 2014.

WF10 Phase 2 Clinical Trial Update
The enrolment for the Phase 2 WF10 clinical trial for the treatment of allergic rhinitis commenced in March 2014 and to-date, 121 patients have been enrolled at 15 sites in Germany.  Enrolment was slower than anticipated due to a late onset to the allergy season in Germany.  The trial is a 160-subject, randomized, double blind, placebo-controlled, 4-arm multi-centre trial to assess the efficacy and safety of a regimen of five WF10 infusions for the treatment of patients with moderate to severe persistent allergic rhinitis.  The Company expects the study to be completed in late 2014 with top-line results available in the first quarter of 2015.

Table of Selected Financial Results
For further details on the results, please refer to Nuvo's Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Statements which are available on the Company's website (www.nuvoresearch.com).

    Three months ended   Six months ended
    June 30,
2014
  June 30,
2013
  Change   June 30,
2014
  June 30,
2013
  Change
(Canadian dollars in thousands,
except per share and share figures)
  $   $   $   $   $   $
Revenue   3,863   3,320   543   6,620   5,571   1,049
Operating Expenses   6,034   5,624   410   11,677   11,040   637
Net loss   (2,307)   (2,220)   (87)   (5,050)   (5,490)   440
Per share - basic and diluted   (0.23)   (0.25)       (0.53)   (0.63)    

Q2 Financial Highlights
Revenue, consisting of product sales, royalties, license fee revenue and research and other contract revenue for the three months ended June 30, 2014 was $3.9 million compared to $3.3 million for the three months ended June 30, 2013.  The increase was attributable to higher product sales of Pennsaid 2% to support the launch in the U.S. and higher Pennsaid product sales to our distributors outside of the U.S.  Total revenue for the six months ended June 30, 2014 was $6.6 million compared to $5.6 million in the comparative period.

Total operating expenses for the three months ended June 30, 2014 increased to $6.0 million from $5.6 million for the three months ended June 30, 2013.  The increase was primarily due to higher General and Administrative (G&A) costs in the quarter.  Total operating expenses for the six months ended June 30, 2014 increased to $11.7 million from $11.0 million in the comparative period.

Cost of Goods Sold (COGS) was unchanged at $1.5 million for the three months ended June 30, 2014 and June 30, 2013.  The Company's gross margin on product sales increased to $0.7 million compared to $0.2 million in the comparative period, due to an increase in Pennsaid and Pennsaid 2% product sales in the quarter.  Gross margin as a percent of product sales increased in the quarter to 32% from 9% in the comparative period.  For the six months ended June 30, 2014, COGS increased to $2.7 million compared to $2.5 million for the six month ended June 30, 2013.

Research and Development expenses were unchanged at $1.5 million and $3.4 million for the three and six months ended June 30, 2014 and June 30, 2013.  In the quarter, the costs associated with the Company's Phase 2 clinical trial for WF10 were offset by the savings realized from the closure of the Company's facility in Salt Lake City and the TPT Group office in 2013.

G&A expenses were $2.9 million for the three months ended June 30, 2014 compared to $2.3 million for the three months ended June 30, 2013.  The increase in the quarter related to an increase in stock-based compensation and professional fees related to the Company's litigation with Mallinckrodt, partially offset by a decrease in non-cash charges related to amortization of the Company's intangible assets.  G&A expenses for the six months ended June 30, 2014 were $5.3 million compared to $4.6 million for the six months ended June 30, 2013.

Net loss was $2.3 million for the three months ended June 30, 2014 compared to $2.2 million for the three months ended June 30, 2013.  The increase in revenue in the quarter was offset by higher operating expenses and a foreign currency loss in the quarter compared to a foreign currency gain in the comparative period.  Net loss was $5.1 million for the six months ended June 30, 2014 compared to $5.5 million for the six months ended June 30, 2013.

Cash and cash equivalents were $10.7 million as at June 30, 2014 compared to $12.6 million as at December 31, 2013.

Cash used in operating activities increased to $2.7 million for the three months ended June 30, 2014 compared to $2.0 million for the three months ended June 30, 2013.  The increase was primarily due to higher investment in non-cash working capital in the quarter related to an increase in accounts receivable due to greater Pennsaid and Pennsaid 2% product sales.  For the six months ended June 30, 2014, cash used in operating activities was $3.6 million compared to $3.8 million for the six months ended June 30, 2013.

Net cash used in financing activities totaled $0.7 million for the three months ended June 30, 2014 compared to $0.5 million for the three months ended June 30, 2013. During both periods, the Company made repayments on finance, lease and other obligations.  Net cash provided by financing activities totaled $1.7 million for the six months ended June 30, 2014 compared to net cash used in financing activities of $0.9 million for the six months ended June 30, 2013.

The number of common shares outstanding as at June 30, 2014 was 10,239,619.

Pennsaid and Pennsaid 2% in the U.S.
According to IMS Health, a provider of dispensed prescription data, during the second quarter of 2014, U.S. prescriptions of Pennsaid 2% were 18,000 with an average of 1.23 bottles per script compared to 6,000 prescriptions in the first quarter of 2014.  Pennsaid 2% was launched on February 10, 2014.  Pennsaid prescriptions were 14,000 in the three months ended June 30, 2014, a 42% decrease from the prescriptions in the first quarter of 2014. The decrease in Pennsaid prescriptions was related to the launch of Pennsaid 2% as Mallinckrodt is working to switch the market from Pennsaid to Pennsaid 2% and the launch of a generic version of Pennsaid in the U.S. in May 2014.

About Nuvo Research Inc.
Nuvo (TSX:NRI) is a specialty pharmaceutical company with a diverse portfolio of products and technologies.  The Company operates two distinct business units: the Topical Products and Technology (TPT) Group and the Immunology Group.  The TPT Group has four U.S. Food and Drug Administration (FDA) approved commercial products, a pipeline of topical and transdermal products focusing on pain and dermatology and four drug delivery platforms that support the development of patented formulations that can deliver actives into or through the skin.  The Immunology Group has two commercial products, a development program for the treatment of allergic rhinitis and an immune system modulation platform that has the potential to support treatments for a broad range of immune system related disorders.  For additional company information visit www.nuvoresearch.com.

Forward-Looking Statements
Certain statements in this news release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to the Company's anticipated use of proceeds from the Private Placement, the Company's future share price and the Company's possible election to accelerate the expiry date of any of the warrants or the brokers warrants and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "outlook", "objective", "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "should", "plans" or "continue", or similar expressions suggesting future outcomes or events. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such statements. Factors that could cause such differences include general business and economic uncertainties and adverse market conditions as well as other risk factors included in the Company's Annual Information Form dated February 20, 2014 under the heading "Risks Factors" and as described from time to time in the reports and disclosure documents filed by the Company with Canadian securities regulatory agencies and commissions. This list is not exhaustive of the factors that may impact the Company's forward-looking statements. These and other factors should be considered carefully and readers should not place undue reliance on the Company's forward-looking statements. As a result of the foregoing and other factors, no assurance can be given as to any such future results, levels of activity or achievements and neither the Company nor any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. The factors underlying current expectations are dynamic and subject to change. Although the forward-looking information contained in this news release is based upon what management believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements.  All forward-looking statements in this news release are qualified by these cautionary statements. The forward-looking statements contained herein are made as of the date of this news release and except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.  

SOURCE Nuvo Research Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, will examine the regulations and provide insight on how it affects technology, challenges the established rules and will usher in new levels of diligence a...
Existing Big Data solutions are mainly focused on the discovery and analysis of data. The solutions are scalable and highly available but tedious when swapping in and swapping out occurs in disarray and thrashing takes place. The resolution for thrashing through machine learning algorithms and support nomenclature is through simple techniques. Organizations that have been collecting large customer data are increasingly seeing the need to use the data for swapping in and out and thrashing occurs ...
As many know, the first generation of Cloud Management Platform (CMP) solutions were designed for managing virtual infrastructure (IaaS) and traditional applications. But that’s no longer enough to satisfy evolving and complex business requirements. In his session at 21st Cloud Expo, Scott Davis, Embotics CTO, will explore how next-generation CMPs ensure organizations can manage cloud-native and microservice-based application architectures, while also facilitating agile DevOps methodology. He wi...
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
yperConvergence came to market with the objective of being simple, flexible and to help drive down operating expenses. It reduced the footprint by bundling the compute/storage/network into one box. This brought a new set of challenges as the HyperConverged vendors are very focused on their own proprietary building blocks. If you want to scale in a certain way, let’s say you identified a need for more storage and want to add a device that is not sold by the HyperConverged vendor, forget about it....
In the enterprise today, connected IoT devices are everywhere – both inside and outside corporate environments. The need to identify, manage, control and secure a quickly growing web of connections and outside devices is making the already challenging task of security even more important, and onerous. In his session at @ThingsExpo, Rich Boyer, CISO and Chief Architect for Security at NTT i3, discussed new ways of thinking and the approaches needed to address the emerging challenges of security i...
Docker containers have brought great opportunities to shorten the deployment process through continuous integration and the delivery of applications and microservices. This applies equally to enterprise data centers as well as the cloud. In his session at 20th Cloud Expo, Jari Kolehmainen, founder and CTO of Kontena, discussed solutions and benefits of a deeply integrated deployment pipeline using technologies such as container management platforms, Docker containers, and the drone.io Cl tool. H...
Cloud adoption is often driven by a desire to increase efficiency, boost agility and save money. All too often, however, the reality involves unpredictable cost spikes and lack of oversight due to resource limitations. In his session at 20th Cloud Expo, Joe Kinsella, CTO and Founder of CloudHealth Technologies, tackled the question: “How do you build a fully optimized cloud?” He will examine: Why TCO is critical to achieving cloud success – and why attendees should be thinking holistically ab...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, will provide a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to...
SYS-CON Events announced today that Datera, that offers a radically new data management architecture, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datera is transforming the traditional datacenter model through modern cloud simplicity. The technology industry is at another major inflection point. The rise of mobile, the Internet of Things, data storage and Big...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, will discuss th...
An increasing number of companies are creating products that combine data with analytical capabilities. Running interactive queries on Big Data requires complex architectures to store and query data effectively, typically involving data streams, an choosing efficient file format/database and multiple independent systems that are tied together through custom-engineered pipelines. In his session at @BigDataExpo at @ThingsExpo, Tomer Levi, a senior software engineer at Intel’s Advanced Analytics ...
SYS-CON Events announced today that Datera will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datera offers a radically new approach to data management, where innovative software makes data infrastructure invisible, elastic and able to perform at the highest level. It eliminates hardware lock-in and gives IT organizations the choice to source x86 server nodes, with business model option...
"Cloud computing is certainly changing how people consume storage, how they use it, and what they use it for. It's also making people rethink how they architect their environment," stated Brad Winett, Senior Technologist for DDN Storage, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, Cloud Expo and @ThingsExpo are two of the most important technology events of the year. Since its launch over eight years ago, Cloud Expo and @ThingsExpo have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors! In this blog post, I provide 7 tips on how, as part of our world-class faculty, you can deliver one of the most popular sessions at our events. But before reading the...